Comparative Pharmacology
Head-to-head clinical analysis: METOCURINE IODIDE versus NORCURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOCURINE IODIDE versus NORCURON.
METOCURINE IODIDE vs NORCURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive nicotinic acetylcholine receptor antagonist at the neuromuscular junction, blocking acetylcholine binding and preventing muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and inducing skeletal muscle paralysis.
Initial dose 0.2 mg/kg IV; maintenance doses of 0.1-0.15 mg/kg IV as needed for neuromuscular blockade.
0.08-0.1 mg/kg IV bolus for intubation; maintenance 0.01-0.015 mg/kg IV every 30-60 min as needed or continuous infusion at 0.06-0.12 mg/kg/hr.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in patients with normal renal function. Prolonged in renal impairment.
Terminal elimination half-life is approximately 1.3-2.2 hours in adults; prolonged in hepatic or renal impairment (up to 3-4 hours in renal failure).
Renal: 85-90% unchanged; biliary/fecal: <5%.
Approximately 40-50% of the dose is excreted unchanged in urine within 24 hours; 20-30% is eliminated in feces as unchanged drug and metabolites; minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker